Target intelligence / Profile preview

UDP-N-acetylglucosamine--undecaprenyl-phosphate N-acetylglucosaminephosphotransferase (WecA) (WecA)

Target
WecA
Molecular classification
Enzyme, Transferase, Phosphoglycosyltransferase (EC 2.7.8.33)
01

Overview

UDP-N-acetylglucosamine--undecaprenyl-phosphate N-acetylglucosaminephosphotransferase, commonly known as WecA, is an essential integral membrane enzyme in many bacteria (UniProt P0AFG6). It catalyzes the initial step in the biosynthesis of various cell envelope components, including the O-antigen of lipopolysaccharides and teichoic acids, by transferring a phospho-N-acetylglucosamine moiety from UDP-GlcNAc to the lipid carrier undecaprenyl phosphate (Price & Momany, 2005). Because this process is vital for maintaining bacterial cell wall integrity and viability, WecA is a significant target for the development of novel antibacterial agents (Al-Dabbagh et al., 2008). However, therapeutic development is complicated by the structural similarity between WecA and its eukaryotic counterpart, DPAGT1, which is involved in N-linked protein glycosylation. Inhibitors like tunicamycin demonstrate potent antibacterial activity but exhibit high toxicity in humans due to this lack of selectivity (Lehrer et al., 2007). Current research focuses on identifying narrow-spectrum or highly selective inhibitors that can bypass these safety concerns while effectively treating resistant bacterial infections.

Other names
WecATagOUDP-GlcNAc:undecaprenyl-phosphate GlcNAc-1-phosphate transferaseGlcNAc-P-P-undecaprenol synthetasePhospho-N-acetylglucosamine-transferase
02

Mechanism of action

Inhibition of the transfer of N-acetylglucosamine-1-phosphate to undecaprenyl phosphate, preventing the formation of essential lipid-linked precursors for the bacterial cell envelope (Price & Momany, 2005).

03

Biological functions

Cell wall biogenesis (UniProt P0AFG6)Lipopolysaccharide biosynthesis (Price & Momany, 2005)O-antigen biosynthesis (Al-Dabbagh et al., 2008)Teichoic acid biosynthesis (Lehrer et al., 2007)Enterobacterial common antigen (ECA) synthesis (UniProt P0AFG6)
04

Disease associations

Bacterial infection (Al-Dabbagh et al., 2008)
05

Safety considerations

Cross-reactivity with human DPAGT1 (GPT) (Lehrer et al., 2007)Cytotoxicity due to inhibition of eukaryotic N-linked glycosylationPotential for narrow therapeutic index
06

Interacting drugs

Tunicamycin (Lehrer et al., 2007)

3 more in the full profile.

Beyond the preview

Go deeper on UDP-N-acetylglucosamine--undecaprenyl-phosphate N-acetylglucosaminephosphotransferase (WecA) (WecA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-N-acetylglucosamine--undecaprenyl-phosphate N-acetylglucosaminephosphotransferase (WecA) (WecA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call